On November 30, 2023, Scindy Pharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as “Scindy Pharmaceutical”) and Levostar Life Sciences (Suzhou) Co., Ltd. (hereinafter referred to as “Levostar”) announced a strategic partnership. The collaboration will leverage Levostar’s technical and market strengths in mRNA synthesis and Scindy Pharmaceutical’s technical expertise and product development experience in the LNP field. The aim is to accelerate the development and promotion of mRNA-LNP drugs and jointly advance the research, development, and industrialization of mRNA drugs. The signing ceremony was attended by Chen Xiaobao, Founder and General Manager of Scindy Pharmaceutical, and Dr. Wu Xin, Founder and CEO of Levostar.
Chen Xiaobao expressed his enthusiasm for the partnership, stating, “We are delighted to establish a strategic partnership with Levostar. They have core technology in the field of mRNA synthesis and we bring to the table our technical advantages and product development experience in the LNP field. This collaboration will create a synergy that accelerates the research and application of mRNA-LNP technology, contributing to the research, development, and industrialization of mRNA drugs in China.”
Dr. Wu Xin, Founder and CEO of Levostar, said: “I am deeply honored to establish a strategic partnership with Scindy Pharmaceutical. Our company specializes in mRNA substrate technology development, and Scindy Pharmaceutical’s expertise in LNP encapsulation will provide us with critical technical support. This collaboration marks the beginning of our mutual progress, which will accelerate the development and promotion of new therapies. I firmly believe that through our close collaboration, we can create a greater impact in the field of biotechnology and jointly promote the development of human health.”
This partnership with Levostar marks another strategic collaboration for Scindy Pharmaceutical following its siRNA-LNP cooperation with GenePharma. It further demonstrates the industry’s recognition and affirmation of Scindy Pharmaceutical’s LNP technology. Looking ahead, Scindy Pharmaceutical will continue to delve into LNP delivery technology, providing comprehensive nanocarrier technology solutions, and using advanced nanodelivery technology to promote basic research and clinical transformation of innovative therapies such as RNA.
About Scindy Pharmaceutical
Scindy Pharmaceutical is a platform-based R&D enterprise with a focus on independent innovative nanocarriers. The company is committed to promoting basic research and clinical transformation of innovative therapies such as RNA through advanced nano-delivery technology. Scindy Pharmaceutical has developed a full-chain nanocarrier technology solution from LNP carriers, extrahepatic targeted delivery technology to pipeline development, driven by its i-Core LNP™ nanocarrier R&D platform.
Since its establishment in 2021, Scindy Pharmaceutical has focused on differentiated pipeline layout in areas such as infectious diseases and rare diseases, and promoted the clinical transformation of innovative technologies. Leveraging its leading LNP platform technology, the company has successively launched new LNP-based gene vector products for cell and gene therapy.
About Levostar
Levostar is a biotechnology company specializing in the production and testing of cell gene therapy products. The company provides breakthrough technologies and comprehensive solutions for the cell gene therapy industry. Levostar offers a wide range of services, including traceability compliance services, plasmid and mRNA production, CGT analysis and testing services, and spot products. The company is committed to accelerating medical innovation, assisting drug development, and keeping diseases away from everyone with its professionalism, integrity, openness, pragmatism, equality, and win-win philosophy.
